Abstract Introduction ESPAKEE complex bacteria are well known as a Multidrug Resistance Organisms that cause difficult mange infections. Management of these infections should be based on the monitoring of resistance profiles to provide appropriate therapy to reduce hospitalization costs and patient improvement. Materials and methods A cross-sectional, retrospective, descriptive study analyzed 179 ESKAPEE bacteria isolated from pediatric patients (0-18 years) between January 1 and December 31, 2023. Laboratory tests utilized VITEK 2.0 technology, reporting Minimal Inhibitory Concentration (MIC) and classifying them as resistant or non-resistant. Descriptive statistics were generated using SPSS v22. Results The study included 179 antibiograms. Among Enterobacter species, E. aerogenes (3) and E. cloacae (17) showed 100% resistance to cefalotin. S. aureus (22) exhibited the highest resistance to Oxacillin (36.4%). Klebsiella pneumoniae (40) demonstrated 97.5% resistance to Ampicillin, followed by resistance to first-generation cephalosporins: cefalotin 62.5%, and third-generation cephalosporins: ceftriaxone and ceftazidime both at 60%. Acinetobacter baumannii (9) showed 100% resistance to Fosfomycin. Pseudomonas aeruginosa (30) displayed 100% resistance to Ceftriaxone, Cefotaxime, and Cefuroxime. Enterococcus faecium (2) exhibited 100% resistance to ciprofloxacin, erythromycin, ampicillin, and levofloxacin, while Enterococcus faecalis (16) showed 50% resistance to tetracycline. E. coli (39) exhibited the highest resistance to Ampicillin (87.2%), while in first-generation cephalosporins: cefalotin 66.7%, third generation: cefotaxime 66.7%, ceftazidime 64.1%, and ceftriaxone 66.7%. Conclusions The ESKAPEE complex species isolated in the hospital displayed diverse resistance profiles against various antibiotic families. Key messages • Monitoring ESKAPEE bacteria’s resistance profiles enables physicians to select appropriate antibiotics at optimal dosages and timings. • Physician should know the rate of resistance of the antibiotics that they use for treatment of ESKAPEE bacteria.